Currently, ALVO's current EPS stands at $0.1, according to the most recent financial reports. For the year 2025, ALVO reported a per-share earnings of $0.1, which marks an increase compared to the EPS of -$0.87 recorded in 2024. ALVO recorded an EPS of -$0.37 for the quarterly period ending on Dec 31, 2025.
In 2025, Alvotech's EPS was $0.1, an increase of 111.5% from -$0.87 in 2024. For the fiscal quarter that ended on Dec 31, 2025, the per-share earnings was -$0.37, reflecting a 54.2% decline compared to the same quarter a year earlier. For the twelve months ending December 2025, the EPS is $0.1. For the year 2024, the yearly earnings per share was -$0.87, marking an increase of 64.2% compared to 2023.
Over the past 12 months, Alvotech has recorded an earnings per share growth of -54.2% (YoY, quarterly).
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| VIVS VivoSim Labs Inc. | 0.75 | 91.2% | N/A | N/A |
| ORMP Oramed Pharmaceuticals Inc | 1.43 | 418.8% | N/A | N/A |
| OMER Omeros Corp | 8.04 | 98.1% | N/A | N/A |
| ALVO Alvotech | 37.4 | 111.5% | N/A | N/A |
| OLMA Olema Pharmaceuticals Inc | N/A | 15% | N/A | N/A |
| ORIC Oric Pharmaceuticals Inc | N/A | 19.7% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.